Natera's Signatera test will identify MRD-positive patients for TransCode's Phase 2a trial of TTX-MC138 in colorectal cancer, targeting an unmet need in patients with no radiographic evidence of disease.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
